Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response
Traditionally, therapies combining DNA-damaging agents and STING agonists have shown potential in treating cancer by enhancing immune response and reshaping the tumor microenvironment. However, until now, creating a single molecular entity housing both…